<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Heart" post="Fail RevHeart Fail RevHeart Failure Reviews1382-41471573-7322Springer USNew York pmcid:"/>
 <result pre="courier ; font-style : italic;} Heart Fail RevHeart Fail RevHeart" exact="Failure" post="Reviews1382-41471573-7322Springer USNew York pmcid: 738312210008 doi: 10.1007/s10741-020-10008-2 : Article"/>
 <result pre="Failure Reviews1382-41471573-7322Springer USNew York pmcid: 738312210008 doi: 10.1007/s10741-020-10008-2 : Article" exact="Heart" post="failure and COVID-19 http://orcid.org/0000-0002-3743-3091BaderFerasbaderf@clevelandclinicabudhabi.ae12ManlaYosef3AtallahBassam4StarlingRandall C5[1], [2], grid.67105.350000 0001 2164"/>
 <result pre="[3], [4], [5], grid.239578.20000 0001 0675 4725Department of Cardiovascular Medicine," exact="Heart" post="and Vascular Institute, Kaufman Center for Heart Failure, Cleveland"/>
 <result pre="[5], grid.239578.20000 0001 0675 4725Department of Cardiovascular Medicine, Heart and" exact="Vascular" post="Institute, Kaufman Center for Heart Failure, Cleveland Clinic, epub:"/>
 <result pre="of Cardiovascular Medicine, Heart and Vascular Institute, Kaufman Center for" exact="Heart Failure," post="Cleveland Clinic, epub: 2020-7-7110(C) , This article is made"/>
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="Organization (WHO) declaration of COVID-19 as a global pandemic. Abstract" exact="Heart" post="failure is a common disease state that can be"/>
 <result pre="as a global pandemic. Abstract Heart failure is a common" exact="disease" post="state that can be encountered at different stages in"/>
 <result pre="the course of a COVID-19 patient presentation. New or existing" exact="heart" post="failure in the setting of COVID-19 can present a"/>
 <result pre="can stem from a variety of mechanisms that involve the" exact="viral" post="entry itself through the ACE2 receptors, direct cardiac injury,"/>
 <result pre="and presentations. A correct understanding of the two-way interaction between" exact="heart" post="failure medications and the infection as well as the"/>
 <result pre="of the two-way interaction between heart failure medications and the" exact="infection" post="as well as the proposed COVID-19 medications and heart"/>
 <result pre="and the infection as well as the proposed COVID-19 medications" exact="and heart" post="failure can result in optimal management. Guideline-directed medical therapy"/>
 <result pre="the infection as well as the proposed COVID-19 medications and" exact="heart" post="failure can result in optimal management. Guideline-directed medical therapy"/>
 <result pre="failure can result in optimal management. Guideline-directed medical therapy for" exact="heart" post="failure should not be interrupted for theoretical concerns but"/>
 <result pre="based on tolerance and clinical presentation. Initiating specific cardiac or" exact="heart" post="failure medications to prevent the infection or mitigate the"/>
 <result pre="Initiating specific cardiac or heart failure medications to prevent the" exact="infection" post="or mitigate the disease is also not an evidence-based"/>
 <result pre="heart failure medications to prevent the infection or mitigate the" exact="disease" post="is also not an evidence-based practice at this time."/>
 <result pre="disease is also not an evidence-based practice at this time." exact="Heart" post="failure patients on advanced therapies including those with heart"/>
 <result pre="time. Heart failure patients on advanced therapies including those with" exact="heart" post="transplantation will particularly benefit from involving the advanced heart"/>
 <result pre="with heart transplantation will particularly benefit from involving the advanced" exact="heart" post="failure team members in the overall management if they"/>
 <result pre="in the overall management if they contract the virus. Keywords" exact="Heart" post="failure COVID-19 Cardiac biomarkers Hemodynamics Introduction Coronavirus disease 2019"/>
 <result pre="management if they contract the virus. Keywords Heart failure COVID-19" exact="Cardiac" post="biomarkers Hemodynamics Introduction Coronavirus disease 2019 (COVID-19) is an"/>
 <result pre="virus. Keywords Heart failure COVID-19 Cardiac biomarkers Hemodynamics Introduction Coronavirus" exact="disease" post="2019 (COVID-19) is an infectious disease caused by severe"/>
 <result pre="Cardiac biomarkers Hemodynamics Introduction Coronavirus disease 2019 (COVID-19) is an" exact="infectious disease" post="caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"/>
 <result pre="biomarkers Hemodynamics Introduction Coronavirus disease 2019 (COVID-19) is an infectious" exact="disease" post="caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"/>
 <result pre="disease 2019 (COVID-19) is an infectious disease caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. It was identified"/>
 <result pre="2019 (COVID-19) is an infectious disease caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [1]. It was identified in"/>
 <result pre="(COVID-19) is an infectious disease caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [1]. It was identified in December"/>
 <result pre="into a global health crisis. The full spectrum of SARS-CoV-2" exact="infections" post="in humans is not fully understood yet, but is"/>
 <result pre="being heavily studied. Patients with previously established comorbidities such as" exact="heart" post="failure (HF) are at a particularly high risk of"/>
 <result pre="a particularly high risk of morbidity and mortality from this" exact="viral infection." post="In this review, we explore the risks associated with"/>
 <result pre="In this review, we explore the risks associated with COVID-19" exact="infection" post="in HF patients and address unique aspects related to"/>
 <result pre="and address unique aspects related to HF management in the" exact="acute" post="and chronic settings when complicating the infection itself. Heart"/>
 <result pre="unique aspects related to HF management in the acute and" exact="chronic" post="settings when complicating the infection itself. Heart failure patients"/>
 <result pre="management in the acute and chronic settings when complicating the" exact="infection" post="itself. Heart failure patients and the risk of COVID-19"/>
 <result pre="the acute and chronic settings when complicating the infection itself." exact="Heart" post="failure patients and the risk of COVID-19 infection In"/>
 <result pre="infection itself. Heart failure patients and the risk of COVID-19" exact="infection" post="In addition to older age, chronic comorbidities increase the"/>
 <result pre="the risk of COVID-19 infection In addition to older age," exact="chronic" post="comorbidities increase the risk of severe COVID-19 infection as"/>
 <result pre="older age, chronic comorbidities increase the risk of severe COVID-19" exact="infection" post="as well as its fatality. The overall global mortality"/>
 <result pre="[2, 3] This becomes particularly concerning for patients with existing" exact="cardiovascular disease" post="who generally experience worse prognosis and a mortality rate"/>
 <result pre="3] This becomes particularly concerning for patients with existing cardiovascular" exact="disease" post="who generally experience worse prognosis and a mortality rate"/>
 <result pre="over 10% in some reports [4]. Based on earlier analyses," exact="cardiovascular disease" post="(CVD) was statistically more prevalent in patients who die"/>
 <result pre="10% in some reports [4]. Based on earlier analyses, cardiovascular" exact="disease" post="(CVD) was statistically more prevalent in patients who die"/>
 <result pre="cardiac biomarkers, namely high-sensitivity troponin I (hs-TNI) above the 99th-percentile" exact="upper" post="reference limit of normal) and these patients were significantly"/>
 <result pre="hospitals from three continents and close to 9000 patients found" exact="coronary artery disease" post="and congestive heart failure (mortality of 15.3%, vs. 5.6%"/>
 <result pre="from three continents and close to 9000 patients found coronary" exact="artery disease" post="and congestive heart failure (mortality of 15.3%, vs. 5.6%"/>
 <result pre="three continents and close to 9000 patients found coronary artery" exact="disease" post="and congestive heart failure (mortality of 15.3%, vs. 5.6%"/>
 <result pre="and close to 9000 patients found coronary artery disease and" exact="congestive heart failure" post="(mortality of 15.3%, vs. 5.6% among those without heart"/>
 <result pre="close to 9000 patients found coronary artery disease and congestive" exact="heart" post="failure (mortality of 15.3%, vs. 5.6% among those without"/>
 <result pre="heart failure (mortality of 15.3%, vs. 5.6% among those without" exact="heart" post="failure; CI, 1.62 to 3.79) as independent predictors of"/>
 <result pre="than healthy subjects [7], which in combination with the widespread" exact="systemic" post="inflammatory response associated with severe COVID-19 infections requires enhanced"/>
 <result pre="with the widespread systemic inflammatory response associated with severe COVID-19" exact="infections" post="requires enhanced cardiac performance and high cardiac output, something"/>
 <result pre="are generally incapable of. Clinical and hemodynamic implications of COVID-19" exact="infection" post="in HF patients Exacerbation of chronic HF Lessons from"/>
 <result pre="hemodynamic implications of COVID-19 infection in HF patients Exacerbation of" exact="chronic" post="HF Lessons from the previous coronavirus and influenza epidemics"/>
 <result pre="Lessons from the previous coronavirus and influenza epidemics suggest that" exact="viral" post="infections can exacerbate a preexisting HF, with multiple studies"/>
 <result pre="from the previous coronavirus and influenza epidemics suggest that viral" exact="infections" post="can exacerbate a preexisting HF, with multiple studies showing"/>
 <result pre="infection, HF patients are at a considerable higher risk of" exact="acute" post="exacerbations, and multiple mechanisms may be responsible for triggering"/>
 <result pre="triggering and aggravating this process (Fig.Â 1). Fig. 1 COVID-19" exact="and heart" post="failure Acute infections result in the release of proinflammatory"/>
 <result pre="and aggravating this process (Fig.Â 1). Fig. 1 COVID-19 and" exact="heart" post="failure Acute infections result in the release of proinflammatory"/>
 <result pre="this process (Fig.Â 1). Fig. 1 COVID-19 and heart failure" exact="Acute" post="infections result in the release of proinflammatory cytokines and"/>
 <result pre="process (Fig.Â 1). Fig. 1 COVID-19 and heart failure Acute" exact="infections" post="result in the release of proinflammatory cytokines and the"/>
 <result pre="with the increased metabolic demand, this can lead to cardiac" exact="depression" post="and either new-onset HF or acute decompensation of chronic"/>
 <result pre="can lead to cardiac depression and either new-onset HF or" exact="acute" post="decompensation of chronic HF [10]. Another contributor to cardiac"/>
 <result pre="cardiac depression and either new-onset HF or acute decompensation of" exact="chronic" post="HF [10]. Another contributor to cardiac depression could be"/>
 <result pre="acute decompensation of chronic HF [10]. Another contributor to cardiac" exact="depression" post="could be the coagulation dysfunction induced by the sepsis"/>
 <result pre="New York hospitals that included over 2000 critically ill patients," exact="systemic" post="anticoagulation was associated with prolonged survival particularly in mechanically"/>
 <result pre="has also been recommended given the aforementioned high risk of" exact="thrombosis" post="in this pandemic [16]. It was also reported that"/>
 <result pre="patients, the virus causes kidney impairment in the setting of" exact="acute" post="kidney injury [17, 18], which may lead to volume"/>
 <result pre="the virus causes kidney impairment in the setting of acute" exact="kidney injury" post="[17, 18], which may lead to volume overload that"/>
 <result pre="may lead to volume overload that may exacerbate a preexciting" exact="chronic" post="HF. Heart failure as a manifestation of COVID-19 infection"/>
 <result pre="to volume overload that may exacerbate a preexciting chronic HF." exact="Heart" post="failure as a manifestation of COVID-19 infection in previously"/>
 <result pre="preexciting chronic HF. Heart failure as a manifestation of COVID-19" exact="infection" post="in previously healthy individuals New onset of HF was"/>
 <result pre="due to the direct effect of the virus or the" exact="systemic" post="inflammation on the heart. Severe acute myocarditis can be"/>
 <result pre="of the virus or the systemic inflammation on the heart." exact="Severe" post="acute myocarditis can be a manifestation of the infection"/>
 <result pre="the virus or the systemic inflammation on the heart. Severe" exact="acute" post="myocarditis can be a manifestation of the infection resulting"/>
 <result pre="virus or the systemic inflammation on the heart. Severe acute" exact="myocarditis" post="can be a manifestation of the infection resulting in"/>
 <result pre="heart. Severe acute myocarditis can be a manifestation of the" exact="infection" post="resulting in cardiogenic shock, which can then result in"/>
 <result pre="myocarditis can be a manifestation of the infection resulting in" exact="cardiogenic shock," post="which can then result in multi-organ dysfunction syndrome (MODS)"/>
 <result pre="in cardiogenic shock, which can then result in multi-organ dysfunction" exact="syndrome" post="(MODS) and death [20]. Moreover, the prothrombotic state previously"/>
 <result pre="in multi-organ dysfunction syndrome (MODS) and death [20]. Moreover, the" exact="prothrombotic state" post="previously discussed can result in pulmonary embolism and thus"/>
 <result pre="[20]. Moreover, the prothrombotic state previously discussed can result in" exact="pulmonary embolism" post="and thus acute right ventricular failure. The use of"/>
 <result pre="state previously discussed can result in pulmonary embolism and thus" exact="acute" post="right ventricular failure. The use of temporary heart pumps"/>
 <result pre="and thus acute right ventricular failure. The use of temporary" exact="heart" post="pumps such as the Impella may be useful in"/>
 <result pre="inflammatory response and sympathetic activation, resulting in a more classic" exact="acute" post="HF decompensation with elevated filling pressures and pulmonary edema"/>
 <result pre="more classic acute HF decompensation with elevated filling pressures and" exact="pulmonary" post="edema [21]. Hemodynamic and diagnostic implications in patients with"/>
 <result pre="edema [21]. Hemodynamic and diagnostic implications in patients with COVID-19" exact="Elevated" post="natriuretic peptides suggest HF with a worse prognosis of"/>
 <result pre="function [22]. If HF is present as part of the" exact="infectious" post="process, optimizing loading conditions is critical. Minimal or very"/>
 <result pre="in these cases. When uncertain, hemodynamics are best assessed through" exact="pulmonary" post="artery catheterization, especially if the diagnosis will change the"/>
 <result pre="CVD risk factors and are associated with significantly higher mortality." exact="Multiple" post="studies from Wuhan in China reported acute cardiac injury"/>
 <result pre="significantly higher mortality. Multiple studies from Wuhan in China reported" exact="acute" post="cardiac injury in 17â€&quot;23% of the population, with overall"/>
 <result pre="North America, Europe) that looked at the prevalence of preexisting" exact="cardiovascular" post="comorbidities, septic shock, ICU admission, cardiac injury, and case"/>
 <result pre="Europe) that looked at the prevalence of preexisting cardiovascular comorbidities," exact="septic shock," post="ICU admission, cardiac injury, and case fertility rate [17â€&quot;19,"/>
 <result pre="Asia, North America, and Europe Study N Preexisting CVD (%)" exact="Shock" post="(%) ICU-admission (%) Cardiac injury (%) CFR (%) Wang"/>
 <result pre="Europe Study N Preexisting CVD (%) Shock (%) ICU-admission (%)" exact="Cardiac" post="injury (%) CFR (%) Wang et al. [23] 138"/>
 <result pre="et al. [32] 100 20 - - 14 19 CVD" exact="cardiovascular disease," post="ICU intensive care unit, CFR case fatality rate Generally,"/>
 <result pre="CFR case fatality rate Generally, the combination between HF and" exact="septic shock" post="would lead to higher mortality rate of 70 to"/>
 <result pre="to 90% when compared with 20% in septic patients without" exact="cardiovascular" post="impairment [33]. Available reports estimated that vasoactive agents were"/>
 <result pre="[18, 19]. Furthermore, a careful clinical assessment of signs of" exact="hypervolemia" post="or hypoperfusion is important in all COVID- 19 patients."/>
 <result pre="important in all COVID- 19 patients. In the case of" exact="cardiogenic shock" post="requiring advanced therapy, it potentially means veno-arterial as opposed"/>
 <result pre="it potentially means veno-arterial as opposed to veno-venous cannulation. Recently," exact="cardiogenic shock" post="was reported by Fried et al. as a complication"/>
 <result pre="al. as a complication during the treatment of COVID 19-related" exact="respiratory" post="failure by veno-venous extra-corporeal membranous oxygenation (VV-ECMO), in which"/>
 <result pre="COVID-19-related cardiopulmonary shock [34]. On the other hand, the severe" exact="respiratory" post="illness induced by COVID-19 (Acute respiratory distress syndrome (ARDS),"/>
 <result pre="other hand, the severe respiratory illness induced by COVID-19 (Acute" exact="respiratory" post="distress syndrome (ARDS), parenchymal lung disease) may lead to"/>
 <result pre="the severe respiratory illness induced by COVID-19 (Acute respiratory distress" exact="syndrome" post="(ARDS), parenchymal lung disease) may lead to pulmonary hypertension"/>
 <result pre="respiratory distress syndrome (ARDS), parenchymal lung disease) may lead to" exact="pulmonary" post="hypertension and subsequent right-sided HF [35]. Most importantly, multi-disciplinary"/>
 <result pre="distress syndrome (ARDS), parenchymal lung disease) may lead to pulmonary" exact="hypertension" post="and subsequent right-sided HF [35]. Most importantly, multi-disciplinary approach"/>
 <result pre="the management of COVID-19 patients with evidence of myocardial injury" exact="Heart" post="failure medications in the setting of COVID-19 infection COVID-19"/>
 <result pre="myocardial injury Heart failure medications in the setting of COVID-19" exact="infection" post="COVID-19 mechanism of cellular entry has implicated an important"/>
 <result pre="are part of the Guideline Directed Medical Therapy (GDMT) for" exact="heart" post="failure with reduced ejection fraction (HFrEF). Similar to the"/>
 <result pre="with reduced ejection fraction (HFrEF). Similar to the previously known" exact="respiratory" post="coronaviruses, SARS-CoV-2 spike glycoproteins bind to angiotensin-converting enzyme 2"/>
 <result pre="but have also been reported to be present in the" exact="heart" post="[38]. With the emergence of the current pandemic, this"/>
 <result pre="have upregulated ACE2 receptors and thus are more prone to" exact="viral" post="uptake or worse outcomes if they contract the infection."/>
 <result pre="pharmacologically induced overexpression of a receptor and a resultant more" exact="viral" post="susceptibility. First, while ACE and ACE2 are similar their"/>
 <result pre="(vasoconstriction, myocardial remodeling) but also its potential role in inducing" exact="acute" post="lung injury; therefore, attenuating the effects of an overactivated"/>
 <result pre="hospitalized with COVID-19, exposure to ACEI/ARB did not affect worsening" exact="disease" post="or mortality [45]. In fact, there are currently ongoing"/>
 <result pre="adoption as part of institutional protocols to manage the COVID-19" exact="infection" post="[49, 50]. Both chloroquine and hydroxychloroquine block a potassium"/>
 <result pre="for sudden cardiac death in the setting of the structural" exact="heart" post="disease itself. This is in addition to being on"/>
 <result pre="sudden cardiac death in the setting of the structural heart" exact="disease" post="itself. This is in addition to being on concomitant"/>
 <result pre="[54], this is due to several factors that include the" exact="disease" post="state itself, being on a loop diuretic, frequent electrolyte"/>
 <result pre="the aforementioned high prevalence of concomitant QTc prolonging medications. Moreover," exact="heart" post="failure patients on advanced therapies may also be on"/>
 <result pre="selected drug-drug interactions between the suggested COVID-19 medications and potential" exact="cardiovascular" post="and transplant medications that are commonly used in HF"/>
 <result pre="CYP2D6 increasing beta blocker concentration âž&quot; monitor for bradycardia and" exact="AV block" post="Antiarrhythmic medications (amiodarone, dofetilide) Higher risk of QTc prolongation"/>
 <result pre="Caring for HF patients while minimizing the risk of COVID-19" exact="infection" post="Care pathways and delivery Remote monitoring The Heart Failure"/>
 <result pre="of COVID-19 infection Care pathways and delivery Remote monitoring The" exact="Heart Failure" post="Society of America released a statement addressing how the"/>
 <result pre="COVID-19 infection Care pathways and delivery Remote monitoring The Heart" exact="Failure" post="Society of America released a statement addressing how the"/>
 <result pre="wide spectrum of HF patients and even mechanical circulatory support" exact="and heart" post="transplant are still followed up properly and safely. This"/>
 <result pre="spectrum of HF patients and even mechanical circulatory support and" exact="heart" post="transplant are still followed up properly and safely. This"/>
 <result pre="to inspect for clinical signs of volume overload such as" exact="lower" post="extremity edema, or even jugular venous distention, which have"/>
 <result pre="home monitoring and charting of daily weights and vitals including" exact="heart" post="rate, blood pressure and oxygen saturation can all aid"/>
 <result pre="times such as during this pandemic is remote monitoring of" exact="pulmonary" post="artery pressure through technologies such as CardioMEMS (St Jude"/>
 <result pre="patient self-management has been previously shown to not only reduce" exact="heart" post="failure related hospitalizations but also lead to higher frequency"/>
 <result pre="before and after the lockdown for COVID-19 reported a significantly" exact="lower" post="incidence during the lockdown period [60]. This raise concerns"/>
 <result pre="of seeking medical attention including hospital care or referral to" exact="heart" post="failure specialists when necessary even during the pandemic. Heart"/>
 <result pre="to heart failure specialists when necessary even during the pandemic." exact="Heart" post="failure and self-care behaviors In the era of a"/>
 <result pre="patients, family members, and healthcare providers to early worsening of" exact="chronic" post="HF, leading to early adjustments that can keep them"/>
 <result pre="alternatives through discussions with physicians when necessary [62]. Unique populations" exact="Heart" post="transplant patients Generally, infections are always a concern in"/>
 <result pre="physicians when necessary [62]. Unique populations Heart transplant patients Generally," exact="infections" post="are always a concern in post-heart transplantation given the"/>
 <result pre="preserve graft function. While immunosuppression increases the likelihood of developing" exact="viral" post="infections such as cytomegalovirus and herpes, acute respiratory viral"/>
 <result pre="graft function. While immunosuppression increases the likelihood of developing viral" exact="infections" post="such as cytomegalovirus and herpes, acute respiratory viral infections"/>
 <result pre="likelihood of developing viral infections such as cytomegalovirus and herpes," exact="acute" post="respiratory viral infections are less pronounced [63]. To date,"/>
 <result pre="of developing viral infections such as cytomegalovirus and herpes, acute" exact="respiratory" post="viral infections are less pronounced [63]. To date, it"/>
 <result pre="developing viral infections such as cytomegalovirus and herpes, acute respiratory" exact="viral" post="infections are less pronounced [63]. To date, it is"/>
 <result pre="viral infections such as cytomegalovirus and herpes, acute respiratory viral" exact="infections" post="are less pronounced [63]. To date, it is unclear"/>
 <result pre="are less pronounced [63]. To date, it is unclear if" exact="heart" post="transplant patients are at increased risk of acquiring the"/>
 <result pre="small study from China [64], Ren et al. observed 87" exact="heart" post="transplant recipients during the pandemic and found that only"/>
 <result pre="the pandemic and found that only four of them had" exact="upper" post="respiratory infections, which were unrelated to COVID-19 in most"/>
 <result pre="pandemic and found that only four of them had upper" exact="respiratory" post="infections, which were unrelated to COVID-19 in most of"/>
 <result pre="patients. It is very likely that the perceived risk of" exact="infection" post="in these patients led them to proactively use measures"/>
 <result pre="the typical clinical presentation of COVID-19 patients who are also" exact="heart" post="transplant recipients, resulting in unusual symptoms such as gastrointestinal"/>
 <result pre="findings with the exception of higher C-reactive protein (CRP) and" exact="lower" post="lymphocyte counts compared with non-heart transplant patients. Reported cases"/>
 <result pre="rates when compared with the general populations [65]. Additionally, COVID-19" exact="infection" post="with myocarditis in a heart transplant recipient can mimic"/>
 <result pre="compared with the general populations [65]. Additionally, COVID-19 infection with" exact="myocarditis" post="in a heart transplant recipient can mimic acute allograft"/>
 <result pre="general populations [65]. Additionally, COVID-19 infection with myocarditis in a" exact="heart" post="transplant recipient can mimic acute allograft rejection. Noninvasive tests"/>
 <result pre="infection with myocarditis in a heart transplant recipient can mimic" exact="acute" post="allograft rejection. Noninvasive tests like gene profiling or donor-derived"/>
 <result pre="in a heart transplant recipient can mimic acute allograft rejection." exact="Noninvasive" post="tests like gene profiling or donor-derived cell-free DNA can"/>
 <result pre="the two entities [67]. A recent case series of 28" exact="heart" post="transplant recipients and a confirmed diagnosis of COVID-19 from"/>
 <result pre="of treatment for this unique population. The International Society for" exact="Heart" post="and Lung Transplantation (ISHLT) guidelines suggest holding the immunosuppressive"/>
 <result pre="transplantation under special considerations according to the acuity of the" exact="disease" post="and organ availability. For donors, current ISHLT recommendations support"/>
 <result pre="is positive or if they have imaging findings suggestive of" exact="viral" post="pneumonitis, which can sometimes precede symptoms and even the"/>
 <result pre="for previously negative tested donors when organ recovery starts [70]." exact="Ventricular" post="assist devices Although cellular immunity was reported to be"/>
 <result pre="device theoretically remains steady even in the setting of a" exact="systemic" post="infection, optimizing preload and afterload is very important to"/>
 <result pre="flow and suction events [74]. Early case reports of COVID-19" exact="infections" post="in LVAD patients highlighted refractory hypoxemia leading to tracheostomy,"/>
 <result pre="76]. An important management issue in these cases was the" exact="limited" post="implementation of prone ventilation, a technique known to be"/>
 <result pre="return, thus worsening RV hemodynamics resulting in progressive HF. Conclusion" exact="Heart" post="failure is common and may be encountered de novo"/>
 <result pre="the clinical course of COVID-19 or in those with preexisting" exact="cardiac disease." post="It is thus imperative to understand the diverse interactions"/>
 <result pre="is thus imperative to understand the diverse interactions between this" exact="disease" post="state and the virus to optimize the management of"/>
 <result pre="these patients. A multi-disciplinary approach that involves members of the" exact="heart" post="failure team may result in optimal understanding and management"/>
 <result pre="failure team may result in optimal understanding and management of" exact="chronic" post="heart failure patients including those on advanced therapies in"/>
 <result pre="team may result in optimal understanding and management of chronic" exact="heart" post="failure patients including those on advanced therapies in the"/>
 <result pre="that they have no conflicts of interest. References References 1.LaiCCShihTPKoWCTangHJHsuehPRSevere" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019"/>
 <result pre="they have no conflicts of interest. References References 1.LaiCCShihTPKoWCTangHJHsuehPRSevere acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19):"/>
 <result pre="have no conflicts of interest. References References 1.LaiCCShihTPKoWCTangHJHsuehPRSevere acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the"/>
 <result pre="N Engl J Med 382(25):e102. 10.1056/NEJMoa2007621 7.NgTMToewsMLImpaired norepinephrine regulation of" exact="monocyte" post="inflammatory cytokine balance in heart failureWorld J Cardiol201681058458927847559 8.KytÃ¶maaSHegdeSClaggettBUdellJARosamondWTemteJNicholKWrightJDSolomonSDVardenyOAssociation"/>
 <result pre="10.1056/NEJMoa2007621 7.NgTMToewsMLImpaired norepinephrine regulation of monocyte inflammatory cytokine balance in" exact="heart" post="failureWorld J Cardiol201681058458927847559 8.KytÃ¶maaSHegdeSClaggettBUdellJARosamondWTemteJNicholKWrightJDSolomonSDVardenyOAssociation of influenza-like illness activity with"/>
 <result pre="J Cardiol201681058458927847559 8.KytÃ¶maaSHegdeSClaggettBUdellJARosamondWTemteJNicholKWrightJDSolomonSDVardenyOAssociation of influenza-like illness activity with hospitalizations for" exact="heart" post="failure: the atherosclerosis risk in communities studyJAMA Cardiol20194436336930916717 9.TufanAGÃœLERAAMatucci-CerinicMCOVID-19,"/>
 <result pre="of influenza-like illness activity with hospitalizations for heart failure: the" exact="atherosclerosis" post="risk in communities studyJAMA Cardiol20194436336930916717 9.TufanAGÃœLERAAMatucci-CerinicMCOVID-19, immune system response,"/>
 <result pre="and repurposing antirheumatic drugsTurk J Med Sci202050SI-162063232299202 10.KumarAParrilloJEKumarAClinical review: myocardial" exact="depression" post="in sepsis and septic shockCrit Care20026650012493071 11.DellingerRPInflammation and coagulation:"/>
 <result pre="M, Fagot Gandet F, Fafi-Kremer S (2020) High risk of" exact="thrombosis" post="in patients with severe SARS-CoV-2 infection: a multicenter prospective"/>
 <result pre="B, Mallah SI, AlMahmeed W (2020) Anticoagulation in COVID-19. Eur" exact="Heart" post="J Cardiovasc Pharmacother 6(4):260â€&quot;261. 10.1093/ehjcvp/pvaa036 16.DeFilippis EM, Reza N,"/>
 <result pre="E, Givertz MM, Lindenfeld J, Jessup M (2020) Considerations for" exact="heart" post="failure care during the coronavirus disease 2019 (COVID-19) pandemic."/>
 <result pre="M (2020) Considerations for heart failure care during the coronavirus" exact="disease" post="2019 (COVID-19) pandemic. JACC Heart Fail S2213-1779(20)30273â€&quot;0. 10.1016/j.jchf.2020.05.006 17.Zhou"/>
 <result pre="failure care during the coronavirus disease 2019 (COVID-19) pandemic. JACC" exact="Heart" post="Fail S2213-1779(20)30273â€&quot;0. 10.1016/j.jchf.2020.05.006 17.Zhou F, Yu T, Du R,"/>
 <result pre="L (2020) Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
 <result pre="from Wuhan, China. Intensive Care Med 46(5):846â€&quot;848. 10.1007/s00134-020-05991-x 21.ScallyCAbbasHAhearnTSrinivasanJMezincescuARuddASpathNYucel-FinnAYuecelROldroydKDospinescuCMyocardial and" exact="systemic" post="inflammation in acute stress-induced (Takotsubo) cardiomyopathyCirculation2019139131581159230586731 22.GaoLJiangDWenXSChengXCSunMHeBYouLNLeiPTanXWQinSCaiGQPrognostic value of"/>
 <result pre="Intensive Care Med 46(5):846â€&quot;848. 10.1007/s00134-020-05991-x 21.ScallyCAbbasHAhearnTSrinivasanJMezincescuARuddASpathNYucel-FinnAYuecelROldroydKDospinescuCMyocardial and systemic inflammation in" exact="acute" post="stress-induced (Takotsubo) cardiomyopathyCirculation2019139131581159230586731 22.GaoLJiangDWenXSChengXCSunMHeBYouLNLeiPTanXWQinSCaiGQPrognostic value of NT-proBNP in patients"/>
 <result pre="23.WangDHuBHuCZhuFLiuXZhangJWangBXiangHChengZXiongYZhaoYClinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€&quot;infected" exact="pneumonia" post="in Wuhan, ChinaJAMA20203231110611069 24.GuanWJNiZYHuYLiangWHOuCQHeJXLiuLShanHLeiCLHuiDSDuBClinical characteristics of coronavirus disease 2019"/>
 <result pre="novel coronavirusâ€&quot;infected pneumonia in Wuhan, ChinaJAMA20203231110611069 24.GuanWJNiZYHuYLiangWHOuCQHeJXLiuLShanHLeiCLHuiDSDuBClinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med2020382181708172032109013 25.HuangCWangYLiXRenLZhaoJHuYZhangLFanGXuJGuXChengZClinical features of"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet20203951022350751332007143 27.Fang Z, Yi"/>
 <result pre="Zhong N, Liu Z (2020) Clinical characteristics of 2019 coronavirus" exact="pneumonia" post="(COVID-19): an updated systematic review. medRxiv 28.GrasselliGZangrilloAZanellaAAntonelliMCabriniLCastelliACeredaDColuccelloAFotiGFumagalliRIottiGBaseline characteristics and"/>
 <result pre="A (2020) Clinical and laboratory findings from patients with COVID-19" exact="pneumonia" post="in Babol North of Iran: a retrospective cohort study."/>
 <result pre="Jain SS, Kirtane A, Masoumi A (2020) The variety of" exact="cardiovascular" post="presentations of COVID-19. Circulation 141(23):1930â€&quot;1936. 10.1161/CIRCULATIONAHA.120.047164 35.DrigginEMadhavanMVBikdeliBChuichTLaracyJBiondi-ZoccaiGBrownTSDer NigoghossianCZidarDAHaytheJBrodieDCardiovascular considerations"/>
 <result pre="the COVID-19 pandemicJ Am Coll Cardiol202075182352237132201335 36.ThygesenKAlpertJSJaffeASChaitmanBRBaxJJMorrowDAWhiteHDFourth universal definition of" exact="myocardial infarction" post="(2018)J Am Coll Cardiol201872182231226430153967 37.Hoffmann M, Kleine-Weber H, Schroeder"/>
 <result pre="39.Fang L, Karakiulakis G, Roth M (2020) Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?"/>
 <result pre="Karakiulakis G, Roth M (2020) Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection? Lancet Respir Med"/>
 <result pre="cardiac angiotensin-converting enzyme 2Circulation.2005111202605261015897343 43.ImaiYKubaKRaoSHuanYGuoFGuanBYangPSaraoRWadaTLeong-PoiHCrackowerMAAngiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature2005436704711211616001071 44.KubaKImaiYRaoSGaoHGuoFGuanBHuanYYangPZhangYDengWBaoLA crucial role of angiotensin converting enzyme"/>
 <result pre="inhibitors with severity or risk of death in patients with" exact="hypertension" post="hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan,"/>
 <result pre="risk of death in patients with hypertension hospitalized for coronavirus" exact="disease" post="2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 5(7):1â€&quot;6."/>
 <result pre="in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19)" exact="infection" post="in Wuhan, China. JAMA Cardiol 5(7):1â€&quot;6. 10.1001/jamacardio.2020.1624 46.ClinicalTrials.gov. Randomized"/>
 <result pre="statement addresses concerns re: using RAAS antagonists in COVID-19 -" exact="American" post="College of Cardiology [Internet]. American College of Cardiology. 2020."/>
 <result pre="RAAS antagonists in COVID-19 - American College of Cardiology [Internet]." exact="American" post="College of Cardiology. 2020. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed 27"/>
 <result pre="Starling RC (2020) Virtual visits for care of patients with" exact="heart" post="failure in the era of COVID-19: a statement from"/>
 <result pre="failure in the era of COVID-19: a statement from the" exact="Heart Failure" post="Society of America. J Card Fail 26(6):448â€&quot;456. 10.1016/j.cardfail.2020.04.008 58.AbnousiFKangGGiacominiJYeungAZarafsharSVesomNAshleyEHarringtonRYongCA"/>
 <result pre="in the era of COVID-19: a statement from the Heart" exact="Failure" post="Society of America. J Card Fail 26(6):448â€&quot;456. 10.1016/j.cardfail.2020.04.008 58.AbnousiFKangGGiacominiJYeungAZarafsharSVesomNAshleyEHarringtonRYongCA"/>
 <result pre="Card Fail 26(6):448â€&quot;456. 10.1016/j.cardfail.2020.04.008 58.AbnousiFKangGGiacominiJYeungAZarafsharSVesomNAshleyEHarringtonRYongCA novel noninvasive method for remote" exact="heart" post="failure monitoring: the EuleriAn video Magnification apPLications In heart"/>
 <result pre="remote heart failure monitoring: the EuleriAn video Magnification apPLications In" exact="heart" post="Failure studY (AMPLIFY)NPJ Digit Med2019211631304351 59.AbrahamWTAdamsonPBBourgeRCAaronMFCostanzoMRStevensonLWStricklandWNeelagaruSRavalNKruegerSWeinerSShavelleDJeffriesBYadavJSWireless pulmonary artery haemodynamic"/>
 <result pre="heart failure monitoring: the EuleriAn video Magnification apPLications In heart" exact="Failure" post="studY (AMPLIFY)NPJ Digit Med2019211631304351 59.AbrahamWTAdamsonPBBourgeRCAaronMFCostanzoMRStevensonLWStricklandWNeelagaruSRavalNKruegerSWeinerSShavelleDJeffriesBYadavJSWireless pulmonary artery haemodynamic monitoring"/>
 <result pre="Magnification apPLications In heart Failure studY (AMPLIFY)NPJ Digit Med2019211631304351 59.AbrahamWTAdamsonPBBourgeRCAaronMFCostanzoMRStevensonLWStricklandWNeelagaruSRavalNKruegerSWeinerSShavelleDJeffriesBYadavJSWireless" exact="pulmonary" post="artery haemodynamic monitoring in chronic heart failure: a randomised"/>
 <result pre="studY (AMPLIFY)NPJ Digit Med2019211631304351 59.AbrahamWTAdamsonPBBourgeRCAaronMFCostanzoMRStevensonLWStricklandWNeelagaruSRavalNKruegerSWeinerSShavelleDJeffriesBYadavJSWireless pulmonary artery haemodynamic monitoring in" exact="chronic" post="heart failure: a randomised controlled trial [published correction appears"/>
 <result pre="(AMPLIFY)NPJ Digit Med2019211631304351 59.AbrahamWTAdamsonPBBourgeRCAaronMFCostanzoMRStevensonLWStricklandWNeelagaruSRavalNKruegerSWeinerSShavelleDJeffriesBYadavJSWireless pulmonary artery haemodynamic monitoring in chronic" exact="heart" post="failure: a randomised controlled trial [published correction appears in"/>
 <result pre="Gislason G, Torp-Pedersen C (2020) Incidence of new-onset and worsening" exact="heart" post="failure before and after the COVID-19 epidemic lockdown in"/>
 <result pre="COVID-19 epidemic lockdown in Denmark: a nationwide cohort study. Circ" exact="Heart" post="Fail 13(6):e007274. 10.1161/CIRCHEARTFAILURE.120.007274 61.UMAPATHI P, CUOMO K, RILEY S,"/>
 <result pre="HUBBARD A, MENZEL K, SAUER E, GILOTRA NA Transforming ambulatory" exact="heart" post="failure care in the coronavirus disease-19 era: initial experience"/>
 <result pre="care in the coronavirus disease-19 era: initial experience from a" exact="heart" post="failure disease management clinic. J Card Fail 26(7):637â€&quot;638. 10.1016/j.cardfail.2020.06.003"/>
 <result pre="the coronavirus disease-19 era: initial experience from a heart failure" exact="disease" post="management clinic. J Card Fail 26(7):637â€&quot;638. 10.1016/j.cardfail.2020.06.003 62.Badreldin HA,"/>
 <result pre="63.Ambrosi P (2020) Comment on â€œEpidemiological and clinical characteristics of" exact="heart" post="transplant recipients during the 2019 coronavirus outbreak in Wuhan,"/>
 <result pre="coronavirus outbreak in Wuhan, Chinaâ€� by Ren et al. J" exact="Heart" post="Lung Transplant 39(7):729. 10.1016/j.healun.2020.04.002 64.Ren ZL, Hu R, Wang"/>
 <result pre="Ren W, Li LC (2020) Epidemiological and clinical characteristics of" exact="heart" post="transplant recipients during the 2019 coronavirus outbreak in Wuhan,"/>
 <result pre="coronavirus outbreak in Wuhan, China: a descriptive survey report. J" exact="Heart" post="Lung Transplant 39(5):412â€&quot;417. 10.1016/j.healun.2020.03.008 65.FernÃ¡ndez-Ruiz M, AndrÃ©s A, Loinaz"/>
 <result pre="Am J Transplant 20(7):1849â€&quot;1858. 10.1111/ajt.15929 66.LiFCaiJDongNFirst cases of COVID-19 in" exact="heart" post="transplantation from ChinaJ Heart Lung Transplant202039549649732362394 67.DeFilippis EM, Farr"/>
 <result pre="10.1111/ajt.15929 66.LiFCaiJDongNFirst cases of COVID-19 in heart transplantation from ChinaJ" exact="Heart" post="Lung Transplant202039549649732362394 67.DeFilippis EM, Farr MA, Givertz MM (2020)"/>
 <result pre="Transplant202039549649732362394 67.DeFilippis EM, Farr MA, Givertz MM (2020) Challenges in" exact="heart" post="transplantation in the era of COVID-19. Circulation 141(25):2048â€&quot;2051. 10.1161/CIRCULATIONAHA.120.047096"/>
 <result pre="G, Uriel N (2020) Characteristics and outcomes of recipients of" exact="heart" post="transplant with coronavirus disease 2019. JAMA Cardiol e202159. 10.1001/jamacardio.2020.2159"/>
 <result pre="Characteristics and outcomes of recipients of heart transplant with coronavirus" exact="disease" post="2019. JAMA Cardiol e202159. 10.1001/jamacardio.2020.2159 69.Guidance for cardiothoracic transplant"/>
 <result pre="JK (2020) Donor organ evaluation in the era of coronavirus" exact="disease" post="2019: a case of nosocomial infection. J Heart Lung"/>
 <result pre="in the era of coronavirus disease 2019: a case of" exact="nosocomial infection." post="J Heart Lung Transplant 39(6):611â€&quot;612. 10.1016/j.healun.2020.04.005 71.AnkersmitHJTugudeaSSpanierTWeinbergADArtripJHBurkeEMFlanneryMManciniDRoseEAEdwardsNMOzMCActivation-induced T-cell death"/>
 <result pre="of coronavirus disease 2019: a case of nosocomial infection. J" exact="Heart" post="Lung Transplant 39(6):611â€&quot;612. 10.1016/j.healun.2020.04.005 71.AnkersmitHJTugudeaSSpanierTWeinbergADArtripJHBurkeEMFlanneryMManciniDRoseEAEdwardsNMOzMCActivation-induced T-cell death and immune"/>
 <result pre="S, Wald J, Atluri P, Birati EY (2020) Novel coronavirus" exact="disease" post="2019 in a patient on durable left ventricular assist"/>
</results>
